ArticleSurgery today2018
Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.
Article in Surgery today, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Significance of Serum Tumor Markers in Esophageal and Gastric Cancers: A Systematic Literature Review.Annals of gastroenterological surgery · 2026Review
- Advances in Chemotherapeutic Potential of Glycoconjugates against Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Unsupervised machine learning reveals prognostic value of dynamic carbohydrate antigen 125 trajectory in gastric cancer.BMC cancer · 2025Article
- Current and evolving practices of carbohydrate antigens in gastric cancer: a narrative review.Translational cancer research · 2025Review
- Differential diagnosis of benign and malignant vertebral compression fractures based on CT radiomics model.Frontiers in oncology · 2025Article
- Prognostic Impact of Perioperative CA125 Status in Gastric Cancer Based on New Cutoff Values.Cureus · 2024Article
- miR-122-IGF-1R signaling allied through the dysregulated lncRNAToxicology reports · 2024Article
- A novel prognostic model to predict OS and DFS of stage II/III gastric adenocarcinoma patients in China.Heliyon · 2022Article
- Review
- Molecular and Circulating Biomarkers of Gastric Cancer.International journal of molecular sciences · 2022Review
- Observational
- Neutrophil-to-lymphocyte ratio and C-reactive protein-to-albumin ratio as prognostic factors for unresectable advanced or recurrent gastric cancer.Langenbeck's archives of surgery · 2022Article
- Association of multiple tumor markers with newly diagnosed gastric cancer patients: a retrospective study.PeerJ · 2022Article
- CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.BMC cancer · 2021Article
- Elevated carbohydrate antigen 125 post-operation as a prognostic marker in gastric cancer patients with stage II-III.Translational cancer research · 2020Article
- Glucose restriction combined with chemotherapy decreases telomere length and cancer antigen-125 secretion in ovarian carcinoma.Oncology letters · 2020Article
- Developments in Carbohydrate-Based Cancer Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Biomarkers of gastric cancer: Current topics and future perspective.World journal of gastroenterology · 2018Review
- Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab.Surgical case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the diagnostic and prognostic value of three tumor markers: carcino-embryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), in the pretreatment serum of patients with unresectable advanced or recurrent gastric cancer.
methodsThe subjects of this retrospective analysis were 245 patients with unresectable advanced or recurrent gastric cancer diagnosed at Kochi Medical School between 2007 and 2015. We ascertained the sensitivity of CEA, CA19-9, and CA125 to identify a certain survival time and then evaluated the relative prognosis of the patients.
resultsThe overall positive rates for each tumor marker in the study group were as follows: 57.6% (141/245) for CEA, 38.4% (94/245) for CA19-9, and 34.3% (84/245) for CA125; the sensitivity of these three biomarkers in combination was 73.1% (179/245). The median survival time of the CA125-positive patients was 4.5 months, which was significantly shorter than that of a normal range group (18.3 months, P < 0.001). Multivariate survival analysis identified that high CA125 was independently associated with a worse prognosis (HR 3.941; 95% CI 2.544-6.106; P < 0.001).
conclusionsPretreatment serum CA125 is a useful prognostic biomarker in patients with unresectable advanced or recurrent gastric cancer. Evaluating a panel of serum tumor biomarkers is a useful diagnostic tool as elevated values might be associated with poor survival.
Indexed as
Identifiers
29043453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.